ヒト免疫不全ウイルスおよび慢性B型肝炎ウイルス感染症とともに生きる参加者におけるベピロビルセンの研究(B-Focus) (B-Focus)
ヒト免疫不全ウイルスおよび慢性B型肝炎ウイルス感染症を患い抗レトロウイルス治療を受けている参加者を対象に、ベピロビルセンによる治療の有効性と安全性を評価するための多施設共同無作為化二重盲検プラセボ対照研究
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Bakersfield、California、アメリカ、93301
- GSK Investigational Site
-
San Francisco、California、アメリカ、94115
- GSK Investigational Site
-
-
Florida
-
Orlando、Florida、アメリカ、32803-1851
- GSK Investigational Site
-
West Palm Beach、Florida、アメリカ、33409
- GSK Investigational Site
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55415
- GSK Investigational Site
-
-
New Jersey
-
Hillsborough、New Jersey、アメリカ、08844
- GSK Investigational Site
-
-
-
-
-
Almagro、アルゼンチン、C1427CEA
- GSK Investigational Site
-
Buenos Aires、アルゼンチン、1023
- GSK Investigational Site
-
Buenos Aires、アルゼンチン、C1425AGC
- GSK Investigational Site
-
Buenos Aires、アルゼンチン、C1181ACI
- GSK Investigational Site
-
La Plata、アルゼンチン、B1900AVG
- GSK Investigational Site
-
Rosario、アルゼンチン、S2002KDR
- GSK Investigational Site
-
-
-
-
-
Bristol Avon、イギリス、BS10 5NB
- GSK Investigational Site
-
London、イギリス、E1 1BB
- GSK Investigational Site
-
London、イギリス、SE5 9RS
- GSK Investigational Site
-
London、イギリス、NW3 2QG
- GSK Investigational Site
-
-
-
-
-
Genova、イタリア、16132
- GSK Investigational Site
-
Milan、イタリア、20157
- GSK Investigational Site
-
Milan、イタリア、20162
- GSK Investigational Site
-
Naples、イタリア、80131
- GSK Investigational Site
-
Roma、イタリア、00153
- GSK Investigational Site
-
Sassari、イタリア、07100
- GSK Investigational Site
-
-
-
-
Ontario
-
Ottawa、Ontario、カナダ、K1H 8L6
- GSK Investigational Site
-
Toronto、Ontario、カナダ、M5G 1K2
- GSK Investigational Site
-
-
Quebec
-
Montreal、Quebec、カナダ、H2L 4P9
- GSK Investigational Site
-
Montreal、Quebec、カナダ、H4A 3J1
- GSK Investigational Site
-
Québec、Quebec、カナダ、G1V 4G2
- GSK Investigational Site
-
-
-
-
-
Barcelona、スペイン、08036
- GSK Investigational Site
-
Córdoba、スペイン、14004
- GSK Investigational Site
-
Madrid、スペイン、28041
- GSK Investigational Site
-
Madrid、スペイン、28040
- GSK Investigational Site
-
Madrid、スペイン、28046
- GSK Investigational Site
-
Madrid、スペイン、28031
- GSK Investigational Site
-
-
-
-
-
Marseille、フランス、13003
- GSK Investigational Site
-
Melun、フランス、77000
- GSK Investigational Site
-
Montpellier、フランス、34295
- GSK Investigational Site
-
Nantes、フランス、44093
- GSK Investigational Site
-
Paris、フランス、75018
- GSK Investigational Site
-
Paris、フランス、75012
- GSK Investigational Site
-
-
-
-
-
Aracaju、ブラジル、49060-010
- GSK Investigational Site
-
Campinas、ブラジル、13034-685
- GSK Investigational Site
-
Curitiba、ブラジル、80810-050
- GSK Investigational Site
-
Manaus、ブラジル、69040-000
- GSK Investigational Site
-
Salvador、ブラジル、40110-060
- GSK Investigational Site
-
São Paulo、ブラジル、04121-000
- GSK Investigational Site
-
-
-
-
-
Ekurhuleni、南アフリカ、1459
- GSK Investigational Site
-
Johannesburg、南アフリカ、2092
- GSK Investigational Site
-
-
KwaZulu-Natal
-
Durban、KwaZulu-Natal、南アフリカ、4052
- GSK Investigational Site
-
-
-
-
-
Banchiau Taipei、台湾、220
- GSK Investigational Site
-
Kaohsiung City、台湾、813
- GSK Investigational Site
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Documented chronic hepatitis B virus (HBV) infection and documented human immunodeficiency virus (HIV)-1 infection greater than equal to (>=) 12 months prior to Screening.
-
Must be on uninterrupted antiretroviral therapy (ART) containing at least tenofovir disoproxil (TDF) or tenofovir alafenamide (TAF) plus lamivudine (3TC) or emtricitabine (FTC) for greater than (>)12 months, with no planned changes to the stable regimen over the duration of the study.
o Switch in ART is permitted >=6 months prior to Screening for reasons not related to loss of HIV or HBV control (e.g., change in formulary, tolerability, side effects).
-
Documented evidence of at least 2 plasma HIV-1 ribonucleic acid (RNA) measurements less than (<) 50 copies per milliliter (copies/mL) are required in the 12 months prior to Screening: 1 within 6 to 12 months prior to Screening and 1 within 6 months prior to Screening.
-
Plasma or serum HBV deoxyribonucleic acid (DNA) concentration must be adequately suppressed, defined as plasma or serum HBV DNA <90 international units per milliliter (IU/mL).
-
Plasma or serum HBsAg concentration >100 IU/mL and <=3000 IU/mL.
-
Plasma HIV-1 RNA concentration must be undetectable, defined as plasma HIV 1 RNA <50 copies/mL.
-
Cluster of differentiation 4 (CD4) count >=350 cells per cubic millimeter (cells/mm^3).
-
Alanine aminotransferase (ALT) <=2 times upper limit of normal (ULN).
Exclusion Criteria:
-
History of or suspected liver cirrhosis and/or evidence of cirrhosis.
-
Diagnosed or suspected hepatocellular carcinoma (HCC).
-
History of extrahepatic disorders possibly related to HBV immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
-
Coinfection with:
-
Hepatitis C virus (HCV) with positive HCV antibody and detectable HCV RNA at Screening.
I. HCV treatment should have completed >12 months prior to Screening.
-
Hepatitis D virus (HDV) defined as positive or equivocal HDV antibody regardless of HDV RNA level.
-
-
Clinically significant abnormalities, aside from HIV-1 infection and chronic HBV infection in medical history (e.g., moderate severe liver disease other than chronic HBV/HIV, acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis coagulopathy) or clinically significant physical examination findings.
-
Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) are excluded unless they complete treatment during the Screening period and 7 days prior to randomization.
-
History of malignancy within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
-
History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause), current or history of an autoimmune condition or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
-
Participants who in the investigator's judgment, have a significant risk of suicide or self-harm.
-
Alcohol or drug abuse/dependence
-
Currently taking, or took within 3 months of Screening, any immunosuppressing drugs (e.g., prednisone), other than a short course of therapy (<=2 weeks) or topical/inhaled steroid use.
-
Participants to whom immunosuppressive treatment, including therapeutic doses of steroids, is contraindicated should not be considered for enrolment in the study.
-
Currently taking, or has taken within 12 months of Screening, any interferon containing therapy.
-
Participants requiring anti coagulation therapies (e.g., warfarin, Factor Xa inhibitors) or anti platelet agents (including but not limited to clopidogrel or aspirin) unless treatment can safely be discontinued throughout duration of study intervention, by the discretion of the investigator. Occasional use is permitted.
-
Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
-
Prior treatment with any oligonucleotide or small interfering ribonucleic acid (siRNA) within 12 months prior to the first dosing day.
-
Prior treatment with bepirovirsen.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Participants receiving Bepirovirsen
Participants will receive bepirovirsen. |
Bepirovirsen will be administered. |
|
プラセボコンパレーター:Participants receiving Placebo
Participants will receive placebo. |
Placebo will be administered. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants achieving hepatitis B virus (HBV) virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medication
時間枠:At study week 60
|
HBV virologic response defined as HBV surface antigen (HBsAg) not detected and HBV deoxyribonucleic acid (DNA) less than (<) lower limit of quantification (LLOQ). |
At study week 60
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants achieving HBV virologic response at the scheduled end of study treatment in absence of rescue medication
時間枠:At study week 24
|
HBV virologic response defined as HBsAg not detected and HBV DNA <LLOQ. |
At study week 24
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:GSK Clinical Trials、GlaxoSmithKline
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 219231
- 2023-509588-25 (その他の識別子:EU CT Number)
- 2023 (米国 NIH グラント/契約)
- 2023-509588-25-00 (レジストリ識別子:CTIS (EU))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD 共有時間枠
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD 共有アクセス基準
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。